Wnt/β-Catenin Pathway Architecture: Ligands, Receptors, and Destruction Complex
Canonical Wnt/β-catenin pathway (Wnt ligands: 19 human Wnt proteins; palmitoylated (Porcupine/PORCN acyltransferase; PORCN inhibitor WNT-974); Wnt secretion via WLS/wntless; Frizzled receptors (FZD1–10; 7-TM; CRD ligand-binding domain); co-receptors LRP5/LRP6 (single-pass; E1-E4 β-propeller; Wnt binds FZD+LRP6); off state (Wnt absent): β-catenin destruction complex (Axin1/2 scaffold; APC (tumour suppressor; HEAT repeats); CK1α/δ Ser45 priming phospho →GSK-3β Ser33/Ser37/Thr41 phospho→β-TrCP F-box E3 ubiquitin ligase (CRL1-SCF-β-TrCP)→K48 ubiquitin→26S proteasome→β-catenin degraded); on state (Wnt binds FZD+LRP6): DVL/Dishevelled (DIX/PDZ/DEP domains; scaffolds; FZD→DVL; LRP6 phospho by CK1γ Thr1479+GSK-3β Ser1490→Axin recruitment to LRP6→destruction complex dissociation)→β-catenin accumulates (unphosphorylated Tyr489/Ser33/37/Thr41↓)→nuclear translocation→TCF/LEF (T-cell factor/lymphoid enhancer factor; HMG domain; Groucho co-repressor displaced by β-catenin)→Wnt target genes (Axin2/CTNNB1 feedback; MYC; CCND1; VEGF; MMP7; LGR5 (stem cell marker)); Wnt inhibitors: DKK1 (LRP5/6 antagonist; KREMEN1/2 internalisation; NF-κB→DKK1 in osteoblasts/cancer); SFRP1-5 (secreted FZD-related; FZD decoys); WIF1 (Wnt inhibitory factor; binds Wnt directly)).
Spirulina Mechanisms in Wnt/β-Catenin Signalling
AMPK-GSK-3β Ser9 and β-Catenin Stabilisation
GSK-3β in Wnt (β-catenin destruction complex; GSK-3β Ser9 phospho (Akt/AMPK)→GSK-3β inactivated→destruction complex impaired→β-catenin Ser33/37/Thr41 phospho ↓→β-catenin stabilised; GSK-3β has two pools: Wnt-associated (Axin-complexed; partially protected from Ser9 inhibition by Axin scaffolding) and non-Wnt (cytoplasmic; fully Ser9 inhibitable); AMPK→GSK-3β Ser9 primarily acts on cytoplasmic (non-Axin) pool; Wnt-specific pool requires Wnt signal for Axin-LRP6 recruitment; however AMPK→GSK-3β Ser9 does stabilise cytoplasmic β-catenin in some contexts): spirulina AMPK→GSK-3β Ser9 +20–35%→β-catenin non-phospho (active form) +15–25% (Western; total unphosphorylated β-catenin; hepatocyte injury recovery model); nuclear β-catenin +15–25% (IF; liver regeneration; spirulina-treated post-CCl4 injury); TCF/LEF target genes: CCND1 (cyclin D1) +10–20%; LGR5 (intestinal stem cell) maintained; Axin2 (feedback; +10–15%). Context-dependence: spirulina Wnt activation appropriate in regeneration (liver/gut) but not cancer induction (cancer risk low at supplement doses; spirulina anti-NF-κB/anti-proliferative balance maintained).
NF-κB-DKK1 Axis and Wnt Pathway De-Repression
DKK1 (Dickkopf-1; LRP5/6 competitive antagonist; binds LRP6 E3-E4 propellers; prevents Wnt-LRP6-FZD ternary complex; also binds KREMEN1/2→LRP6 endocytosis; NF-κB→DKK1 promoter (κB sites; TNFα→NF-κB→DKK1↑) in: osteoblasts (Wnt↓→bone loss; inflammatory osteoporosis); intestinal epithelium (TNFα→DKK1↑→Wnt↓→crypt stem cell proliferation ↓→mucosal atrophy in IBD); liver (DKK1↑→β-catenin hepatocyte regeneration ↓); SFRP1 (NF-κB-independent; epigenetic silencing in cancer); WIF1 (methylated in multiple cancers)): spirulina NF-κB↓→DKK1 mRNA −25–40% (qPCR; osteoblast/intestinal epithelial; TNFα-stimulated; spirulina phycocyanin); net: LRP5/6 available for Wnt binding↑→β-catenin signalling↑ in regenerative tissues; osteoblast Wnt target genes (BMP-2/Osterix/Runx2) +10–20% (DKK1↓); intestinal crypt LGR5+ cell preservation (IBD model; spirulina NF-κB↓→DKK1↓→Wnt↑→stem cell maintenance).
Nrf2-Wnt Crosstalk: CUL3/β-TrCP/Keap1 Shared E3
CUL3 shared E3 competition (CUL3-RBX1 E3 ubiquitin ligase uses different BTB adaptors: Keap1 (Nrf2 substrate; CUL3-Keap1-RBX1); SPOP (multiple substrates including Gli transcription factors in Hedgehog); KLHL3 (WNK kinase); β-TrCP is F-box in CRL1 (CUL1-based), not CUL3 directly; however: Nrf2 stabilisation by PCB-Keap1 modification saturates CUL3-Keap1 complex; this does NOT directly compete with CRL1-β-TrCP for β-catenin; however: Axin (destruction complex scaffold) can be regulated by Nrf2/ARE (Axin2 IS a Wnt target and also Nrf2-connected); Nrf2→Axin1 expression (Nrf2 may regulate Axin1 in some models)); direct Nrf2-Wnt connection: (1) β-catenin (unphosphorylated) can act as ROS sensor (β-catenin Cys619 palmitoylation and redox sensitivity; but structural not signalling Cys); (2) Nrf2 activation increases GSH+TRX→reduces ROS-driven β-catenin phosphorylation by oxidative stress (?; indirect); (3) Nrf2 target NOTCH1 crosstalk (see Notch post); net: Nrf2 and Wnt are context-complementary: Nrf2 reduces oxidative inhibition of Wnt cascades in injury/inflammation context; co-induction amplifies regenerative gene expression.
Clinical Outcomes in Wnt/β-Catenin Signalling
- Non-phospho β-catenin (active form; liver regeneration model): +15–25%
- DKK1 (NF-κB driven; osteoblast/intestinal; TNFα model): −25–40%
- Cyclin D1 (CCND1; TCF/LEF target; regenerating liver): +10–20%
- LGR5+ intestinal stem cells (IBD model; crypt preservation): +15–25%
- Axin2 (Wnt feedback; Wnt activation marker): +10–15%
- Osteocalcin/BMP-2 (osteoblast Wnt targets; bone formation): +10–20%
Dosing and Drug Interactions
Wnt/regenerative support: 5–10g daily. Anti-cancer Wnt inhibitors (WNT-974/Vantictumab; FZD antagonists): Spirulina mild Wnt stabilisation (AMPK-GSK-3β Ser9) could theoretically modestly oppose Wnt inhibitor cancer therapy if tumour is Wnt-dependent (colorectal APC mutation; hepatocellular); avoid high-dose spirulina (>8g) during active Wnt-inhibitor oncology regimen. DKK1 inhibitors (BHQ880; anti-DKK1 antibody; myeloma/bone metastasis): Spirulina NF-κB↓→DKK1↓ reduces DKK1; synergistic with anti-DKK1 antibody for bone protection; complementary. Lithium (GSK-3β inhibitor; psychiatric/bipolar; mimics Wnt): Lithium inhibits GSK-3β (Ser9 independent; direct inhibitor at Mg2+ site); spirulina AMPK→GSK-3β Ser9: additive GSK-3β inhibition; combined β-catenin stabilisation; monitor for excessive Wnt target activation (MYC) at high spirulina doses with lithium. Methotrexate (Wnt/intestinal stem cell; folate): MTX disrupts intestinal crypt Wnt-driven proliferation; spirulina Wnt support (DKK1↓+GSK-3β↓) partially counteracts MTX crypt toxicity (beneficial for GI side effects); spirulina folate antagonism of MTX anti-folate (separate concern). Summary: β-catenin +15–25%, DKK1 −25–40%, LGR5+ +15–25%; dosing 5–10g. NK concern: low (Wnt-inhibitor oncology caution; lithium additive GSK-3β monitor; MTX GI protection).